1. Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420–432
2. Amgen Inc (2010a) Xgeva (denosumab) injection [package insert]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s007lbl.pdf . Accessed 8 Feb 2011
3. Amgen Inc (2010b) Xgeva™ (denosumab) significantly improved bone metastasis-free survival in men with prostate cancer [press release]. http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2010&releaseID=1507379 . Accessed 8 Feb 2011
4. Amgen Europe BV (2011) XGEVA 120 mg solution for injection [summary of product characteristics]. http://www.ema.europa.eu/docs/en_GB/document.library/EPAR_-_Product_Information/human/002173/WC500110381.pdf . Accessed 21 Oct 2011
5. Anand A, Scher HI, Beer TM, et al (2010) Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naive patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. J Clin Oncol 28(suppl):353 s, Abstract 4546